COVID-19 Treatment Information
Monoclonal antibody treatments may help people fight mild to moderate COVID-19 infections by easing symptoms and preventing hospitalization. Broward Health is pleased to partner with community physicians to expand access to monoclonal antibody treatment for qualifying patients receiving care outside of the Broward Health system. The treatment is provided at no cost to the patient and consists of a 45 minute infusion, followed by a one-hour post observation period. To be scheduled, eligible patients must have a physician referral and be approved for treatment.
Broward Health currently offers bamlanivimab monoclonal antibody therapy. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the unapproved products bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in qualifying adults and pediatric patients.
Please review the EUA fact sheet for more information on the treatment and consult with your healthcare provider to determine if you are a candidate. This treatment is most effective when given immediately following COVID-19 diagnosis. This information is provided as a community education resource.
Broward Health has expanded ordering access to bamlanivimab and etesevimab monoclonal antibody therapy for the treatment of certain cases of mild to moderate COVID-19. Community physicians and APRNs who are not on staff at Broward Health may order bamlanivimab.
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved products bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.